Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 524

1.

Excessive ADAM17 activation occurs in uremic patients and may contribute to their immunocompromised status.

Yashiro M, Ohya M, Mima T, Nakashima Y, Kawakami K, Sonou T, Tatsuta K, Yamano Y, Negi S, Shigematsu T.

Immun Inflamm Dis. 2020 Mar 17. doi: 10.1002/iid3.298. [Epub ahead of print]

2.

Pulse oximetry saturation can predict prognosis of idiopathic pulmonary fibrosis.

Takei R, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, Furukawa T, Takahashi O, Chiba H, Takahashi H, Kondoh Y.

Respir Investig. 2020 Mar 8. pii: S2212-5345(20)30023-X. doi: 10.1016/j.resinv.2019.12.010. [Epub ahead of print]

PMID:
32160945
3.

Nicotine inhibits expression of Prrx1 in pituitary stem/progenitor cells through epigenetic regulation, leading to a delayed supply of growth-hormone-producing cells.

Hibara A, Yamaguchi T, Kojima M, Yamano Y, Higuchi M.

Growth Horm IGF Res. 2020 Apr;51:65-74. doi: 10.1016/j.ghir.2020.02.003. Epub 2020 Feb 19.

PMID:
32146343
4.

Synthesis of One Double Bond-Inserted Retinal Analogs and Their Binding Experiments with Opsins: Preparation of Novel Red-Shifted Channelrhodopsin Variants.

Okitsu T, Yamano Y, Shen YC, Sasaki T, Kobayashi Y, Morisawa S, Yamashita T, Imamoto Y, Shichida Y, Wada A.

Chem Pharm Bull (Tokyo). 2020;68(3):265-272. doi: 10.1248/cpb.c19-01005.

5.

Tuberculous Spondylitis Caused by Intravesical Bacillus Calmette-Guerin Therapy.

Minakata T, Nakano Y, Tamura S, Kazuki Y, Hayakawa K, Hayakawa T, Oota T, Fuzimoto T, Yamano Y, Takii T.

Intern Med. 2020;59(5):733-737. doi: 10.2169/internalmedicine.3288-19. Epub 2020 Mar 1.

6.

STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.

Tahara T, Watanabe A, Yutani M, Yamano Y, Sagara M, Nagai S, Saito K, Yamashita M, Ihara M, Iida A.

Bioorg Med Chem. 2020 Mar 15;28(6):115347. doi: 10.1016/j.bmc.2020.115347. Epub 2020 Jan 28.

PMID:
32044231
7.

Probable UIP pattern on chest CT: Is it sufficient for a diagnosis of IPF?

Fukihara J, Kondoh Y, Brown KK, Kimura T, Kataoka K, Matsuda T, Yamano Y, Suzuki A, Furukawa T, Sumikawa H, Takahashi O, Johkoh T, Tanaka T, Fukuoka J, Hashimoto N, Hasegawa Y.

Eur Respir J. 2020 Feb 6. pii: 1802465. doi: 10.1183/13993003.02465-2018. [Epub ahead of print]

PMID:
32029448
8.

Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient.

Takeda R, Ishigaki T, Ohno N, Yokoyama K, Kawamata T, Fukuyama T, Araya N, Yamano Y, Uchimaru K, Tojo A.

Int J Hematol. 2020 Jan 13. doi: 10.1007/s12185-019-02815-7. [Epub ahead of print]

PMID:
31930455
9.

Identification of 5'-untranslated regions that function as effective translational enhancers in monocotyledonous plant cells using a novel method of genome-wide analysis.

Yamasaki S, Suzuki A, Yamano Y, Kawabe H, Ueno D, Demura T, Kato K.

Plant Biotechnol (Tokyo). 2018 Dec 25;35(4):365-373. doi: 10.5511/plantbiotechnology.18.0903a.

10.

Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease.

Takei R, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, Johkoh T, Takahashi O, Kondoh Y.

Respir Investig. 2020 Mar;58(2):83-90. doi: 10.1016/j.resinv.2019.10.004. Epub 2019 Dec 6.

PMID:
31813784
11.

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.

Yamano Y.

Clin Infect Dis. 2019 Nov 13;69(Supplement_7):S544-S551. doi: 10.1093/cid/ciz827.

12.

Usefulness of new diagnostic criteria for chronic hypersensitivity pneumonitis established on the basis of a Delphi survey: A Japanese cohort study.

Takei R, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, Johkoh T, Tabata K, Fukuoka J, Kondoh Y.

Respir Investig. 2020 Jan;58(1):52-58. doi: 10.1016/j.resinv.2019.10.001. Epub 2019 Nov 9.

PMID:
31718936
13.

Lasianosides A-E: New Iridoid Glucosides from the Leaves of Lasianthus verticillatus (Lour.) Merr. and Their Antioxidant Activity.

Al-Hamoud GA, Saud Orfali R, Perveen S, Mizuno K, Takeda Y, Nehira T, Masuda K, Sugimoto S, Yamano Y, Otsuka H, Matsunami K.

Molecules. 2019 Nov 5;24(21). pii: E3995. doi: 10.3390/molecules24213995.

14.

Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids.

Yamauchi J, Sato T, Yagishita N, Araya N, Hasegawa D, Tsutsumi S, Nagasaka M, Coler-Reilly A, Inoue E, Takata A, Hasegawa Y, Yamano Y.

J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):321-323. doi: 10.1136/jnnp-2019-321955. Epub 2019 Oct 29. No abstract available.

PMID:
31662348
15.

Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden.

Anan K, Iso Y, Oguma T, Nakahara K, Suzuki S, Yamamoto T, Matsuoka E, Ito H, Sakaguchi G, Ando S, Morimoto K, Kanegawa N, Kido Y, Kawachi T, Fukushima T, Teisman A, Urmaliya V, Dhuyvetter D, Borghys H, Austin N, Van Den Bergh A, Verboven P, Bischoff F, Gijsen HJM, Yamano Y, Kusakabe K.

ChemMedChem. 2019 Nov 20;14(22):1894-1910. doi: 10.1002/cmdc.201900478. Epub 2019 Nov 12.

PMID:
31657130
16.

Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan.

Tsutsumi S, Sato T, Yagishita N, Yamauchi J, Araya N, Hasegawa D, Nagasaka M, Coler-Reilly ALG, Inoue E, Takata A, Yamano Y.

Orphanet J Rare Dis. 2019 Oct 21;14(1):227. doi: 10.1186/s13023-019-1212-4.

17.

The Nature of the HTLV-1 Provirus in Naturally Infected Individuals Analyzed by the Viral DNA-Capture-Seq Approach.

Katsuya H, Islam S, Tan BJY, Ito J, Miyazato P, Matsuo M, Inada Y, Iwase SC, Uchiyama Y, Hata H, Sato T, Yagishita N, Araya N, Ueno T, Nosaka K, Tokunaga M, Yamagishi M, Watanabe T, Uchimaru K, Fujisawa JI, Utsunomiya A, Yamano Y, Satou Y.

Cell Rep. 2019 Oct 15;29(3):724-735.e4. doi: 10.1016/j.celrep.2019.09.016.

18.

Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.

Tamaki K, Sato T, Tsugawa J, Fujioka S, Yagishita N, Araya N, Yamauchi J, Coler-Reilly ALG, Nagasaka M, Hasegawa Y, Yamano Y, Tsuboi Y.

Front Microbiol. 2019 Sep 11;10:2110. doi: 10.3389/fmicb.2019.02110. eCollection 2019.

19.

Discovery of an Extremely Potent Thiazine-Based β-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose.

Tadano G, Komano K, Yoshida S, Suzuki S, Nakahara K, Fuchino K, Fujimoto K, Matsuoka E, Yamamoto T, Asada N, Ito H, Sakaguchi G, Kanegawa N, Kido Y, Ando S, Fukushima T, Teisman A, Urmaliya V, Dhuyvetter D, Borghys H, Van Den Bergh A, Austin N, Gijsen HJM, Yamano Y, Iso Y, Kusakabe KI.

J Med Chem. 2019 Oct 24;62(20):9331-9337. doi: 10.1021/acs.jmedchem.9b01140. Epub 2019 Oct 8.

PMID:
31549838
20.

Establishment of a Comprehensive Information Infrastructure and a Support Organization for Rare Disease Research in Japan (RADDAR-J).

Yamaguchi I, Furusawa Y, Kawaguchi T, Yagishita N, Tanzawa K, Yamano Y, Matsuda F.

Stud Health Technol Inform. 2019 Aug 21;264:1080-1083. doi: 10.3233/SHTI190391.

PMID:
31438091
21.

Eudesmane-type sesquiterpene glycosides: sonneratiosides A-E and eudesmol β-D-glucopyranoside from the leaves of Sonneratia alba.

Katsutani K, Sugimoto S, Yamano Y, Otsuka H, Matsunami K, Mizuta T.

J Nat Med. 2020 Jan;74(1):119-126. doi: 10.1007/s11418-019-01353-0. Epub 2019 Aug 7.

PMID:
31392565
22.

Metabolism of 3-[5'-deoxy-5'-(dimethylarsinoyl)-β-ribofuranosyloxy]-2-hydroxypropylene glycol in an artificial digestive system.

Hata A, Hasegawa M, Yamauchi T, Otomo Y, Miura M, Yamanaka K, Yamano Y, Fujitani N, Endo G.

Heliyon. 2019 Jul 19;5(7):e02079. doi: 10.1016/j.heliyon.2019.e02079. eCollection 2019 Jul.

23.

National platform for Rare Diseases Data Registry of Japan.

Furusawa Y, Yamaguchi I, Yagishita N, Tanzawa K, Matsuda F, Yamano Y; RADDAR‐J Research and Development Group.

Learn Health Syst. 2019 Jan 31;3(3):e10080. doi: 10.1002/lrh2.10080. eCollection 2019 Jul.

24.

In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models.

Nakamura R, Ito-Horiyama T, Takemura M, Toba S, Matsumoto S, Ikehara T, Tsuji M, Sato T, Yamano Y.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e02031-18. doi: 10.1128/AAC.02031-18. Print 2019 Sep.

25.

Isolation of Sesquiterpene-Amino Acid Conjugates, Onopornoids A-D, and a Flavonoid Glucoside from Onopordum alexandrinum.

Sugimoto S, Yamano Y, Desoukey SY, Katakawa K, Wanas AS, Otsuka H, Matsunami K.

J Nat Prod. 2019 Jun 28;82(6):1471-1477. doi: 10.1021/acs.jnatprod.8b00948. Epub 2019 Jun 14.

PMID:
31199638
26.

Four New Flavonoids Isolated from the Aerial Parts of Cadaba rotundifolia Forssk. (Qadab).

Abdulaziz Al-Hamoud G, Saud Orfali R, Sugimoto S, Yamano Y, Alothyqi N, Mohammed Alzahrani A, Matsunami K.

Molecules. 2019 Jun 9;24(11). pii: E2167. doi: 10.3390/molecules24112167.

27.

Proteomic analysis of hippocampal proteins in acrylamide-exposed Wistar rats.

Nagashima D, Zhang L, Kitamura Y, Ichihara S, Watanabe E, Zong C, Yamano Y, Sakurai T, Oikawa S, Ichihara G.

Arch Toxicol. 2019 Jul;93(7):1993-2006. doi: 10.1007/s00204-019-02484-9. Epub 2019 May 23.

PMID:
31123803
28.

8-Pyrenylvinyl Adenine Controls Reversible Duplex Formation between Serinol Nucleic Acid and RNA by [2 + 2] Photocycloaddition.

Murayama K, Yamano Y, Asanuma H.

J Am Chem Soc. 2019 Jun 19;141(24):9485-9489. doi: 10.1021/jacs.9b03267. Epub 2019 May 23.

PMID:
31117655
29.

Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.

Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF.

Diagn Microbiol Infect Dis. 2019 Aug;94(4):321-325. doi: 10.1016/j.diagmicrobio.2019.03.003. Epub 2019 Mar 23.

30.

A 10-Year History of Anti-Smoking Campaigns and Enlightenment Activities for Chronic Obstructive Pulmonary Disease for Citizens at the Plaza in Ebina City.

Sato Y, Taniuchi N, Kaburaki S, Aruga N, Kubota K, Seike M, Yamano Y, Gemma A.

J Nippon Med Sch. 2019;86(1):32-37. doi: 10.1272/jnms.JNMS.2019_86-6.

31.

[Changes in the number of female presentations at the annual meeting of the Japan Society for Occupational Health].

Okubo S, Yamauchi T, Yamano Y.

Sangyo Eiseigaku Zasshi. 2019 May 25;61(3):108-114. doi: 10.1539/sangyoeisei.2018-029-S. Epub 2019 Mar 13. Japanese. No abstract available.

32.

Estimation of the effective reproduction number of influenza based on weekly reports in Miyazaki Prefecture.

Yamauchi T, Takeuchi S, Yamano Y, Kuroda Y, Nakadate T.

Sci Rep. 2019 Feb 22;9(1):2539. doi: 10.1038/s41598-019-39057-w.

33.

The Relationship between Walking Speed and Step Length in Older Aged Patients.

Morio Y, Izawa KP, Omori Y, Katata H, Ishiyama D, Koyama S, Yamano Y.

Diseases. 2019 Feb 2;7(1). pii: E17. doi: 10.3390/diseases7010017.

34.

Risk of Human T-Cell Leukemia Virus Type 1 Infection in Kidney Transplantation.

Yamauchi J, Yamano Y, Yuzawa K.

N Engl J Med. 2019 Jan 17;380(3):296-298. doi: 10.1056/NEJMc1809779. No abstract available.

PMID:
30650320
35.

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.

Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF.

Int J Antimicrob Agents. 2019 Apr;53(4):456-466. doi: 10.1016/j.ijantimicag.2018.11.007. Epub 2018 Nov 22.

36.

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.

Ito A, Nishikawa T, Ota M, Ito-Horiyama T, Ishibashi N, Sato T, Tsuji M, Yamano Y.

J Antimicrob Chemother. 2019 Feb 1;74(2):539. doi: 10.1093/jac/dky482. No abstract available.

37.

Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model.

Stainton SM, Monogue ML, Tsuji M, Yamano Y, Echols R, Nicolau DP.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01040-18. doi: 10.1128/AAC.01040-18. Print 2019 Feb.

38.

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).

Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, Sahm DF.

Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.

39.

Proposed method of histological separation between connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonias.

Ozasa M, Ichikawa H, Sato S, Tanaka T, Johkoh T, Kataoka K, Yamano Y, Kondoh Y, Nakamura H, Kawakami A, Bychkov A, Taniguchi H, Fukuoka J.

PLoS One. 2018 Nov 5;13(11):e0206186. doi: 10.1371/journal.pone.0206186. eCollection 2018.

40.

Carotenoid Profiling of a Red Seaweed Pyropia yezoensis: Insights into Biosynthetic Pathways in the Order Bangiales.

Koizumi J, Takatani N, Kobayashi N, Mikami K, Miyashita K, Yamano Y, Wada A, Maoka T, Hosokawa M.

Mar Drugs. 2018 Nov 1;16(11). pii: E426. doi: 10.3390/md16110426.

41.
43.

Pinopsin evolved as the ancestral dim-light visual opsin in vertebrates.

Sato K, Yamashita T, Kojima K, Sakai K, Matsutani Y, Yanagawa M, Yamano Y, Wada A, Iwabe N, Ohuchi H, Shichida Y.

Commun Biol. 2018 Oct 1;1:156. doi: 10.1038/s42003-018-0164-x. eCollection 2018.

44.

Metabolic abnormalities in adult T-cell leukemia/lymphoma and induction of specific leukemic cell death using photodynamic therapy.

Oka T, Mizuno H, Sakata M, Fujita H, Yoshino T, Yamano Y, Utsumi K, Masujima T, Utsunomiya A.

Sci Rep. 2018 Oct 8;8(1):14979. doi: 10.1038/s41598-018-33175-7.

45.

Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis.

Teramachi R, Kondoh Y, Kataoka K, Taniguchi H, Matsuda T, Kimura T, Yokoyama T, Yamano Y, Furukawa T, Sakamoto K, Hashimoto N, Hasegawa Y.

Respir Med. 2018 Oct;143:147-152. doi: 10.1016/j.rmed.2018.09.011. Epub 2018 Sep 13.

PMID:
30261987
46.

Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.

Ito A, Nishikawa T, Ota M, Ito-Horiyama T, Ishibashi N, Sato T, Tsuji M, Yamano Y.

J Antimicrob Chemother. 2018 Nov 1;73(11):3049-3052. doi: 10.1093/jac/dky317. Erratum in: J Antimicrob Chemother. 2019 Feb 1;74(2):539.

47.

Red-Tuning of the Channelrhodopsin Spectrum Using Long Conjugated Retinal Analogues.

Shen YC, Sasaki T, Matsuyama T, Yamashita T, Shichida Y, Okitsu T, Yamano Y, Wada A, Ishizuka T, Yawo H, Imamoto Y.

Biochemistry. 2018 Sep 25;57(38):5544-5556. doi: 10.1021/acs.biochem.8b00583. Epub 2018 Sep 12.

PMID:
30153419
48.

FBLIM1 enhances oral cancer malignancy via modulation of the epidermal growth factor receptor pathway.

Toeda Y, Kasamatsu A, Koike K, Endo-Sakamoto Y, Fushimi K, Kasama H, Yamano Y, Shiiba M, Tanzawa H, Uzawa K.

Mol Carcinog. 2018 Dec;57(12):1690-1697. doi: 10.1002/mc.22889. Epub 2018 Sep 5.

PMID:
30129678
49.

Development of reference material with assigned value for human T-cell leukemia virus type 1 quantitative PCR in Japan.

Kuramitsu M, Okuma K, Nakashima M, Sato T, Sasaki D, Hasegawa H, Umeki K, Kubota R, Sasada K, Sobata R, Matsumoto C, Kaneko N, Tezuka K, Matsuoka S, Utsunomiya A, Koh KR, Ogata M, Ishitsuka K, Taki M, Nosaka K, Uchimaru K, Iwanaga M, Sagara Y, Yamano Y, Okayama A, Miura K, Satake M, Saito S, Watanabe T, Hamaguchi I.

Microbiol Immunol. 2018 Oct;62(10):673-676. doi: 10.1111/1348-0421.12644.

PMID:
30125970
50.

Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity.

Sato T, Yagishita N, Tamaki K, Inoue E, Hasegawa D, Nagasaka M, Suzuki H, Araya N, Coler-Reilly A, Hasegawa Y, Tsuboi Y, Takata A, Yamano Y.

Front Microbiol. 2018 Jul 25;9:1651. doi: 10.3389/fmicb.2018.01651. eCollection 2018.

Supplemental Content

Loading ...
Support Center